-
The two-dose vaccine uses a protein-based technology, unlike the mRNA approach used in vaccines made by Pfizer and Moderna. CDC approval is still needed for ages 12-17.
-
Adults who haven't gotten any COVID-19 shots should consider the new option, the agency said Tuesday. The spike protein vaccine is more typical than the mRNA types being broadly used against COVID.
-
Advisers to the Food and Drug Administration overwhelmingly voted to recommend that it authorize Novavax's two-dose vaccine against COVID-19.
-
Instead of putting genetic instructions into people whose cells then make a viral protein, the vaccines from Novavax, Medicago and Sanofi carry a spike protein payload.